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Reporting National Outcomes After Esophagectomy and
Gastrectomy According to the Esophageal Complications
Consensus Group (ECCG)
Leonie R. van der Werf, MD, Linde A. D. Busweiler, MD, PhD,y Johanna W. van Sandick, MD, PhD,z
Mark I. van Berge Henegouwen, MD, PhD,y and Bas P. L. Wijnhoven, MD, PhD, the Dutch Upper GI Cancer
Audit (DUCA) group
Objective: This nation-wide population-based study aimed to report postop-
erative morbidity and mortality after esophagectomy and gastrectomy in the
Netherlands according to the definitions of the Esophagectomy Complica-
tions Consensus Group (ECCG).
Background: To standardize international outcome reporting in esophageal
surgery, the ECCG developed a standardized outcomes set.
Methods: For this national cohort study, all patients undergoing esophagec-
tomy or gastrectomy for cancer between 2016 and 2017 were selected from
the Dutch Upper gastrointestinal Cancer Audit. In a random sample of
hospitals, data completeness and accuracy were validated by reabstraction
of the data. The investigated outcomes in the present study were postoperative
complications, major complications (Clavien–Dindo gradeIII), and 30-day
mortality, according to definitions of the ECCG.
Results: A total of 2545 patients from 22 hospitals were included. The
completeness of the Dutch Upper gastrointestinal Cancer Audit was estimated
at 99.8%. Data accuracy on different items was 94% to 100%. After
esophagectomy, 1046 of 1617 patients (65%) had a postoperative complica-
tion including 468 patients (29%) with a major complication. Most common
complications were pneumonia (21%), esophago-enteric leak from anasto-
mosis, staple line or localized conduit necrosis (19%), and atrial dysrhythmia
(15%). The 30-daymortality was 1.7%. After gastrectomy, 397 of 928 patients
(42%) had a postoperative complication including 180 patients (19%) with a
major complication. Most common complications were pneumonia (12%),
esophago-enteric leak from anastomosis, staple line or localized conduit
necrosis (9%), and acute delirium (5%). The 30-day mortality was 4.4%.
Conclusions: Reporting complications according to the ECCG platform is
feasible in the Netherlands and facilitates international benchmarking.
Keywords: clinical auditing, esophagectomy, esophagectomy complication
consensus group, gastrectomy, outcomes-set
(Ann Surg 2020;271:1095–1101)
F or resectable nonmetastatic esophageal and gastric cancer, resec-tion is as yet the cornerstone of treatment. Both esophagectomy
and gastrectomy are associated with high postoperative morbidity
rates. To evaluate quality of care, in several European countries
clinical audits are used.1–3 Feedback of audit data to the specialist
may improve outcomes by stimulating best practices and the initia-
tion of improvement programs for health care pathways. For a
reliable comparison of outcomes between hospitals on a national
level and to compare patterns of care and outcomes between coun-
tries, it is important to use uniform definitions.
To standardize outcome reporting in esophageal surgery, the
Esophagectomy Complications Consensus Group (ECCG) devel-
oped a standardized outcomes-set.4 In 2017, in 24 hospitals in
different countries the outcomes after esophagectomy were collected
according to the definitions of the ECCG.5
In January 2016, the definitions of the ECCG were introduced
in the Dutch Upper gastrointestinal Cancer Audit (DUCA).1 The
outcomes including postoperative complications, readmission, and
30-day mortality were registered according to the definitions of the
ECCG platform for both esophagectomy and gastrectomy. At that
time, an international standardized outcomes-set for gastrectomywas
lacking. Hence, the ECCG outcomes-set was applied for patients
who underwent esophagectomy and gastrectomy also because the
type and severity of complications that occur after both procedures is
somewhat comparable.
The primary aim of this study was to report postoperative
morbidity and mortality after esophagectomy and gastrectomy in the
Netherlands according to the ECCG definitions and to report the
completeness and accuracy of the DUCA data. Second, the outcomes
after esophagectomy in the DUCAwere compared with the reported
outcomes of the initial ECCG dataset.5
METHODS
Study Design
For this national cohort study, patient data were retrieved
from the DUCA database. Dutch hospitals are mandated to
register all esophageal (including gastro-esophageal junction) or
gastric cancer patients undergoing surgery with the intent of
a resection.
Data Verification
Before evaluation of the DUCA data, it is important to test
whether the outcomes are valid. The reliability of data of the data
was verified in 2016. Participation of hospitals in this data verifi-
cation process was voluntary. Outcomes of this data verification
were the completeness and accuracy of registered data. A random
sample of 15 participating hospitals was visited by an external data
verification employee and a random sample of operated patients
with esophageal or gastric cancer was checked for inclusion in the
DUCA database. Per hospital, 30 patients operated in 2016 were
selected. If less than 30 patients were operated, all available
patients were selected. Reabstraction of data from the electronic
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patient dossier took place for all selected patients. The original data
was compared with data registered in the DUCA.6 In the present
study, the accuracy with regard to registration of postoperative
complications, 30-day mortality, reinterventions, readmissions,
number of lymph nodes, resections margin, and ASA score (the
physical status classification according to the American Society of
Anesthesiologists) was tested. The accuracy was estimated by the
number of discrepancies found against the total number of patients
in the sample.
Patients
All patients undergoing an esophagectomy of gastrectomy in
the Netherlands between January 2016 and December 2017 for
esophageal or gastric cancer were included in this study. Patients
with a palliative bypass procedure were excluded. Also, patients with
missing data regarding complications or other essential elements of
the registration including date of birth, survival status at 30 days after
surgery or date of discharge (in case of a hospital stay of >30 d)
were excluded.
Outcomes
The primary outcome was frequency of postoperative com-
plications. The severity of the complications was defined according
to Clavien–Dindo.7 Complications grade IIIa or higher were defined
as major complications. The secondary outcomes were hospital stay,
duration of stay at the intensive care unit, the frequency of reinter-
ventions, 30-day and/or in-hospital mortality, readmissions, the
number of retrieved lymph nodes, surgical resection margins, and
the ASA score. For all patients who underwent an esophagectomy,
the outcomes were compared with the outcomes of the ECCG as
recently reported.5
Statistical Methods
Patient and tumor characteristics of all included patients were
reported according to the type of resection (esophagectomy or
gastrectomy) using frequencies and percentages. Also, all postoper-
ative outcomes were described using frequencies and percentages.
The outcomes after esophagectomy in the DUCA were compared
with the reported outcomes of the ECCG dataset5 using chi-square
analyses. Statistical analyses of the present study were performed
using Microsoft Excel for Mac (version 15.41). Statistical signifi-
cance was defined as P < 0.05.
RESULTS
Data Verification
The completeness of the DUCA was estimated at 99.8%
(Table 1). In a sample of 408 patients, 1 patient who should have
been registered according to the inclusion criteria of theDUCAwasnot
registered. Complications were accurately registered in 382 of 407
patients (94%). In 25 patients (6%) no complication was registered in
the DUCA, whereas in the electronical patient file a complication was
reported. Thirty-day and/or in-hospital mortality was accurately reg-
istered in 406 of 407 patients (98.8%). In 13 of 407 patients (3%), a
complicated postoperative course (defined as a complication leading to
prolonged hospital stay (>21 d), reintervention or death) was not
registered in theDUCAdatabase but was extracted from the electronic
patient files. All verified variables are shown in Table 1.
Patients
From January 2016 to December 2017, a total of 1617 patients
undergoing an esophagectomy and 928 patients undergoing a gas-
trectomy were registered in the DUCA. Eight patients were excluded
due to missing data. Patient, disease, and treatment characteristics are
summarized in Tables 2 and 3. Minimally invasive techniques were
used in 86% of patients undergoing an esophagectomy and in 58% of
patients undergoing a gastrectomy. Fifty-two percent of esophagec-
tomies was performed via a transthoracic approach. In 43% of all
gastrectomies, a total gastrectomy was performed.
Outcomes After Esophagectomy
Sixty-five percent of patients who underwent an esophagec-
tomy had a postoperative complication (Table 4). Clavien–Dindo
grade III or higher complications occurred in 29% of all patients
(Table 5). Most common complications were pneumonia (21%), leak
from the anastomosis, staple line or localized conduit necrosis (19%),
and atrial dysrhythmia (15%). All complications are presented in
Supplementary Table 1 (Supplemental Digital Content, http://links.
lww.com/SLA/B561). The median stay at the intensive care unit was
2 days (interquartile range: 1–4), and median hospital stay was
TABLE 1. Results of External Data Verification
Completeness of Data
Sample Size: 408
Registered Wrongly Not Registered Completeness
n n %
Included in DUCA 407 1 99.8%
Accuracy of Data
Sample Size: 407
Correctly Registered Wrongly Registered Missing Accuracy
n n n %
Complications 382 25 0 94%
30-d/in-hospital mortality 406 1 0 99.8%
Reinterventions 394 13 0 97%
Complications leading to
prolonged hospital stay
(>21 d), reintervention
or death
394 13 0 97%
Readmission 390 12 5 97%
Number of lymph nodes 394 13 0 97%
Resection margins 394 11 2 97%
ASA score 379 28 0 93%
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TABLE 2. Patient and Disease Characteristics, According to Type of Resection: Esophagectomy (for ECCG1 and DUCA) and
Gastrectomy DUCA only Are Shown
ECCG Esophagectomy1 DUCA Esophagectomy DUCA Gastrectomy
n % n % n %
Total 2704 1617 928
Sex
Male 2096 78% 1228 76% 561 61%
Female 607 22% 388 24% 367 40%
Unknown 1 0% 0 0%
Age (in yr)
40 or less 66 2% 6 0% 25 3%
41–50 217 8% 76 5% 53 6%
51–60 721 27% 316 20% 129 14%
61–70 1100 41% 739 46% 227 25%
71–80 532 20% 451 28% 355 38%
more than 80 67 3% 29 2% 139 15%
Body mass index
<18.5 184 7% 47 3% 34 4%
18.5–25 1085 40% 657 41% 420 45%
25–30 908 34% 642 40% 329 36%
30þ 526 20% 265 16% 136 15%
Unknown 6 0% 9 1%
ASA score
I 412 15% 255 16% 113 12%
II 1249 46% 1012 63% 526 57%
III 992 37% 340 21% 273 29%
IV 49 2% 7 0% 15 2%
V 1 0% 0 0% 0 0%
Unknown 3 0% 1 0%
Charlson Comorbidity Score
0 754 47% 411 44%
1 385 24% 191 21%
2þ 478 30% 326 35%
Comorbidities
Myocardial infarction 146 5% 86 5% 66 7%
Congestive heart failure 124 5% 12 1% 19 2%
Chronic Pulmonary Disease 285 11% 326 20% 155 17%
Peripheral Vascular Disease 185 7% 73 5% 53 6%
Diabetes Mellitus (uncomplicated) 348 13% 221 14% 160 17%
Diabetes Mellitus (end-organ damage) 16 1% 13 6% 5 3%
Moderate to Severe Renal Disease 35 1% 21 1% 29 3%
Pathology (indication for surgery)
Benign 97 4%
Malignant 2585 96%
Other, including perforations 21 1%
Location (ECCG)
At the GE junction 762 28%
Proximal 1/2 of esophagus 304 11%
Distal 1/2 of esophagus 1519 56%
Location (DUCA)
Cervical (C15.0) 1 0% 0 0%
Proximal (C15.3) 14 1% 0 0%
Mid (C15.4) 226 14% 0 0%
Distal (C15.5) 1087 67% 3 0%
Gastro-esophageal junction (C16.0) 261 16% 32 3%
Fundus (C16.1) 18 1% 69 7%
Corpus (C16.2) 1 0% 281 30%
Antrum (C16.3) 0 0% 365 39%
Pylorus (C16.4) 0 0% 80 9%
Total stomach 0 0% 44 5%
Rest stomach/anastomosis 0 0% 34 4%
Unknown (stomach) 6 0% 1 0%
Missing 3 0% 19 2%
Unknown 2 0% 2 0%
1. Low DE, Kuppusamy MK, Alderson D, et al. Benchmarking Complications Associated with Esophagectomy. Ann Surg 2017.
ASA indicates American Society of Anaestesiologists.
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TABLE 3. Pathological- and Treatment Characteristics, According to Type or Resection: Esophagectomy (for ECCG1 and DUCA)
and Gastrectomy DUCA only Are Shown
ECCG Esophagectomy1 DUCA Esophagectomy DUCA Gastrectomy
N % n % n %
Total 2704 1617 928
Pathological tumor stage
pT0–2 1242 65% 966 60% 341 37%
pT3 1075 42% 592 37% 327 35%
pT4 78 3% 21 1% 236 25%
Missing 0 0% 38 2% 24 3%
Pathological node stage
pN 1477 57% 957 59% 421 45%
pNþ 1101 42% 622 39% 485 52%
pNx 7 0% 4 0% 7 1%
Missing 34 2% 15 2%
Pathological metastases stage
pM 2170 84% 1528 95% 796 86%
pMþ 46 2% 23 1% 61 7%
Not apllicable 0 0% 48 3% 54 6%
pMx 369 14% 18 1% 17 2%
Timing of surgery
Elective 2680 99% 1610 100% 895 96%
Urgent 3 0% 25 3%
Emergency 23 1% 3 0% 8 1%
Unknown 1 0% 0 0%
Neoadjuvant therapy
No 545 21% 105 7% 379 42%
Chemotherapy 763 30% 86 5% 502 55%
Chemoradiotherapy 1192 46% 1417 88% 28 3%
Radiotherapy 5 0% 6 0% 0 0%
Unknown 0 0% 1 0%
Definitive chemoradiotherapy 80 3%
Surgical approach
Open 1407 52% 229 14% 394 43%
MI 1296 48% 1388 86% 534 58%
Esophagectomy (open)
Transhiatal 283 20% 109 48%
Transthoracic 1124 80% 120 52%
Esophagectomy (MI)
Abdomen only 521 40% 222 16%
Chest only 144 11% 60 4%
Abdomen and chest 631 49% 1106 80%
Gastrectomy (open and MI)
Total 402 43%
Partial 526 57%
Site of anastomosis
Chest 1641 61% 876 54% 65 7%
Neck 1025 38% 696 43% 2 0%
Abdomen 7 0% 807 87%
Other/none 37 1% 38 2% 54 6%
Conduit/reconstruction
Stomach 2564 95% 1567 99% 4 0%
Colon 34 1% 4 0% 1 0%
Small bowel 72 3% 0 0% 2 0%
Esophagojejunostomy (Roux-Y) 5 0% 394 44%
Gastroenterostomy (BII or Roux-Y) 0 0% 483 54%
Other/none 33 1% 9 1% 12 1%
Resection margins
R0 Microscopic radical 2414 93% 1532 95% 820 89%
R1 microscopic irradical 157 6% 65 4% 83 9%
R2 Locoregional residual tumor 14 1% 1 0% 4 0%
Not applicable 8 1% 8 1%
Unknown 2 0% 2 0%
1. Low DE, Kuppusamy MK, Alderson D et al. Benchmarking Complications Associated with Esophagectomy. Ann Surg 2017.
MI indicates minimally invasive.
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11 days (interquartile range: 9–18). The 30-day mortality rate was
1.7% and the 30-day/in-hospital mortality rate was 2.4%.
In comparison with the reported outcomes of the ECCG,5 the
overall complication rate was significantly higher in the DUCA (65%
vs 59%, P < 0.001). Also, pneumonia and leak from anastomosis,
staple line, or localized conduit necrosis, occurred more often
(respectively, 21% vs 15%, P < 0.001 and 19% vs 11%, P <
0.001) (Fig. 1). Hospital readmission within 30 days after discharge
TABLE 4. Outcomes of the DUCA (Dutch Upper Gastrointestinal Cancer Audit) According to Type of Resection
Esophagectomy Gastrectomy
Total (n¼ ) 1617 928
Median [IQR] Median [IQR]
Hospital stay (d) 11 [9–18] 8 [6–13]
ICU stay (d) 2 [1–4] 0 [0–1]
n % n %
Intraoperative complication 89 5.5% 34 3.7%
Postoperative complication 1046 65% 397 43%
Reintervention 420 26% 186 20%
Radiological 170 51
Endoscopic 187 54
Reoperation 208 121
In-hospital/30-d mortality 38 2.4% 49 5.3%
30-d mortality 27 1.7% 41 4.4%
Readmission 233 15% 123 14%
Postoperative complication Clavien Dindo grade III or more 468 29% 180 19%
ICU indicates intensive care unit.
TABLE 5. Severity of Complications in the DUCA (Dutch Upper Gastrointestinal Cancer Audit) According to Type of Resection
Esophagectomy Gastrectomy
Complication Severity n % 95% CI n % 95% CI
No complications 605 37% 35% 40% 562 61% 57% 64%
Grade I 150 9% 8% 11% 39 4% 3% 6%
Grade II 379 23% 21% 26% 130 14% 12% 16%
Grade IIIa 192 12% 10% 14% 51 6% 4% 7%
Grade IIIb 128 8% 7% 9% 66 7% 6% 9%
Grade IVa 110 7% 6% 8% 23 3% 2% 4%
Grade IVb 11 1% 0% 1% 5 1% 0% 1%
Grade V 27 2% 1% 2% 35 4% 3% 5%
Grade unknown 15 1% 1% 2% 17 2% 1% 3%
FIGURE 1. Comparison of outcomes after esophagectomies, DUCA versus ECCG.
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occurred in 15% of patients, significantly more often compared with
the ECCG cohort (11%, P < 0.001). The 30-day mortality rate was
1.7% versus 2.4% in the ECCG cohort (P¼0.10).
Outcomes After Gastrectomy
Forty-three percent of patients who underwent a gastrec-
tomy experienced a postoperative complication (Table 4). Clav-
ien–Dindo grade III or higher complications occurred in 19% of
patients (Table 5). Most common complications were pneumonia
(12%), esophago-enteric leak from anastomosis, staple line or
localized conduit necrosis (9%), and acute delirium (5%). All
complications are presented in Supplementary Table 1 (Supple-
mental Digital Content, http://links.lww.com/SLA/B561). The
severity of 4 outcome measures according to the ECCG4 is
presented in Supplementary Table 2, Supplemental Digital Con-
tent, http://links.lww.com/SLA/B561. The median stay at the
intensive care unit stay was 0 days (interquartile range: 0–1),
and median hospital stay was 8 days (interquartile range: 6–13).
Hospital readmission within 30 days after discharge occurred in
14% of patients. The 30-day mortality rate was 4.4%, and the 30-
day/in-hospital mortality was 5.3%.
DISCUSSION
This study with DUCA data shows that reporting complica-
tions according to the ECCG definitions can be achieved on a
national level. Data verification showed that the completeness and
accuracy of data in the DUCA were high. Overall, complications
after esophagectomy and gastrectomy occurred in 65% and 43% of
patients, respectively. Major complications (Clavien–Dindo grade
III or higher) occurred in 29% and 19% of patients, respectively. The
most common complications after esophagectomy were pneumonia,
esophago-enteric leak, and dysrhythmia atrial. After gastrectomy,
pneumonia, esophago-enteric leak, and acute delirium were the most
common complications.
Recently, the outcomes of 24 high volume hospitals partici-
pating in the ECCG were published.5 Compared with these data,
overall complication rates, pneumonia rates, and esophago-enteric
leakage rates were significantly higher in the DUCA. Different
explanations may exist for these discrepancies.
First, differences in patient and treatment characteristics
exist between the ECCG cohort and DUCA cohort which might
have influenced the occurrence of complications. From previous
studies with DUCA data, it is known that higher age, ASA score,
body mass index, Nþ status, proximal-mid esophageal tumor-
location, and open transthoracic procedures are associated with an
increased risk for postoperative complications.8,9 Some of these
factors were more frequently present in the DUCA, for example,
30% of patients were older than 70 years old (vs 23% in the ECCG
cohort). However, in the ECCG cohort, patients with ASA III or
higher were more frequently present then in the DUCA (39% vs
21%).
The second difference was the percentage of patients that
was treated with neoadjuvant chemoradiotherapy. In the DUCA,
88% of patients were treated with neoadjuvant chemoradiother-
apy, versus 46% in the ECCG cohort. In the literature, some
studies regarding neoadjuvant chemoradiotherapy have reported
no significant differences in complication rates between neoadju-
vant chemoradiotherapy and neoadjuvant chemotherapy alone or
no neoadjuvant therapy.10–12 However, Klevebro et al12 reported a
higher frequency of severe complications after neoadjuvant che-
moradiotherapy in comparison with neoadjuvant chemotherapy
alone. It has been suggested that radiotherapy affects the lung
tissue and may increase pulmonary complications.13 The differ-
ence in type and frequency of neoadjuvant therapy could be an
explanation of the higher pneumonia rate in the DUCA versus the
ECCG cohort. A study with combined datasets and correction for
differences in case-mix could potentially answer this issue.
Another difference between both cohorts was the type of
esophagectomy. In the DUCA 86% of patients underwent a mini-
mally invasive esophagectomy versus 48% in the ECCG. The TIME
trial, a randomized trial evaluating minimally invasive versus open
transthoracic esophagectomy, showed that in-hospital pulmonary
infections occurred significantly less frequent after minimally inva-
sive esophagectomy (12% vs 34%).14 A previous Dutch study
showed that during the implementation of minimally invasive esoph-
agectomies in the Netherlands there were no differences in pulmo-
nary complications and 30-day/in-hospital mortality between
minimally invasive versus open gastrectomy. However, the same study
showed higher anastomotic leakage rates and reintervention rates after
minimally invasive gastrectomy.15 The introduction of minimally
invasive surgery and the associated learning curve that goes with
it,16 might have influenced the complication rate. Nonetheless, in
2015, 84% of the registered esophagectomies in the DUCA was
performed with minimally invasive techniques and, since the current
study only reports data of 2016 and2017, it could be thatmost surgeons
might already have completed their learning curve in this period.
However, it is important to keep in mind that learning curve until
proficiencymight bemuch longer than initiallywas expected.16 Future
studies are needed to evaluate the ‘‘real’’ length of the learning curve.
Also the approach of esophagectomy differed between the
DUCA and ECCG cohorts. The transhiatal approach was more
favourite in the DUCA cohort than in the ECCG cohort: 48% versus
20%, respectively. As reported in a meta-analysis of Hulscher et al,17
the transhiatal approach and cervical anastomosis is associated with a
higher frequency of anastomotic leakage and vocal cord paralysis. In
the transthoracic group in this meta-analysis, there was more peri-
operative blood loss, pulmonary complications, chyle leak, and
wound infections. Thus, the difference in favored approaches
between the DUCA and ECCGmight explain the higher anastomotic
leakage rate in the DUCA database. Nonetheless, the higher pneu-
monia rate in the DUCA could not be explained by the differences in
surgical approach.
The annual hospital volume of the participating hospitals in
the ECCG has been described as all ‘‘high volume.’’ In the DUCA, in
2016, the annual hospital volume varied each year. In 2016, 9 of 22
hospitals performed 40 or more resections and 5 hospitals performed
less than 20 resections.18 Differences in annual hospital volume may
influence outcomes. However, further studies are needed to evaluate
whether these differences can explain the variation in outcomes
between the cohorts.
Due to the use of a standardized outcomes set, the DUCA
outcomes after esophagectomies could be compared with the ECCG
outcomes fairly. For outcomes after gastrectomies, at the time of the
implementation of the ECCG outcomes, there was no standardized
international consensus set and the ECCG outcomes were also
incorporated for patients after gastrectomy. To our knowledge, the
ECCG outcomes set has not been used for reporting outcomes after
gastrectomy in other cohorts. Recently, a specific standardized out-
comes set for gastric cancer surgery was published with the intent to
facilitate international comparison.19 The intent is to implement this
standardized set of definitions in the DUCA because it potentially
facilitates international comparison.
An international comparison of Dutch results after esopha-
gectomy and gastrectomy has been done previously. The results of
the DUCA were compared with the results of the Swedish NREV
(Nationellt Kvalitetsregister matstrups-och magsa¨ckscancer).20
However, the results of the registries at that time were not standard-
ized, which makes comparison not really reliable.
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The 30-day mortality in the DUCA database was 1.7% after
esophagectomy and 4.4% after gastrectomy. In comparison with
the outcomes of the ECCG cohort, the mortality after esophagec-
tomies was not significantly different. The 30-day mortality after
gastrectomy and esophagectomy was also reported in the annual
report of the British ‘‘National Oesophago Gastric Cancer Audit.’’
Between 2007 and 2009 and between 2013 and 2015, the 30-day
mortality after esophagectomies was 3.8% (95% confidence inter-
val: 3.1%–4.7%) and 1.6% (95% confidence interval: 1.2%–
2.1%), respectively. After gastrectomy it was 4.5% (95% confi-
dence interval: 3.4%–5.7%) and 1.9% (95% confidence interval
1.3%–2.7%), respectively. In the annual report of the National
Oesophago Gastric Cancer Audit, no clarification was given for
this improvement in 30-day mortality after esophagectomy and
gastrectomy. It would be interesting to evaluate the underlying
processes; to direct a strategy to also improve 30-day mortality
after gastrectomy in the Netherlands.
In conclusion, evaluation of quality of care is important,
especially for high complex, low-volume procedures such as esoph-
agectomy and gastrectomy. Reporting outcomes using standardized
definitions is an essential step toward reliable results. Furthermore, it
enables international comparisons that could help to reveal signifi-
cant differences in outcomes and to identify factors which could be
improved. A more widespread adoption of the ECCG platform could
be recommended to improve international benchmarking in
esophageal surgery.
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